Importance of nonpulmonary vein foci in catheter ablation for paroxysmal atrial fibrillation  by Hayashi, Kentaro et al.
Importance of nonpulmonary vein foci in catheter
ablation for paroxysmal atrial ﬁbrillation
Kentaro Hayashi, MD, Yoshimori An, MD, Michio Nagashima, MD, Kenichi Hiroshima, MD,
Masatsugu Ohe, MD, PhD, Yu Makihara, MD, Kennosuke Yamashita, MD,
Schoichiro Yamazato, MD, Masato Fukunaga, MD, Koichiro Sonoda, MD, PhD,
Kenji Ando, MD, PhD, Masahiko Goya, MD, PhD
From the Department of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.BACKGROUND Pulmonary vein (PV) isolation is an established
treatment strategy for paroxysmal atrial ﬁbrillation (PAF). However,
the recurrence rate of PAF is 8% to 37%, despite repeated
procedures, and the catheter ablation strategy for PAF with non-
PV foci is unclear.
OBJECTIVE The purpose of this study was to assess the PAF
ablation strategy for non-PV foci.
METHODS The study included 304 consecutive patients under-
going PAF ablation (209 males, age 63.0 10.4 years) divided into
3 groups: group 1 (245 patients) with no inducible non-PV foci;
group 2 (34 patients) with atrial ﬁbrillation (AF) originating from
non-PV foci and all the foci successfully ablated; and group 3
(25 patients) with AF originating from non-PV triggers, but without
all foci being ablated or with persistently inducible AF.
RESULTS Mean follow-up period was 26.9  11.8 months,
and AF recurrence rates since the last procedure were 9.8%,
8.8%, and 68.0% in groups 1, 2, and 3, respectively. There was
no statistically signiﬁcant difference in recurrence rate betweenAddress reprint requests and correspondence: Dr. Kentaro Hayashi,
Department of Cardiology, Kokura Memorial Hospital, 3-2-1 Asano
Kokurakita-ku, Kitakyushu, Japan. E-mail address: sg-kentaro@kf6.so-
net.ne.jp.
1547-5271 B 2015 Heart Rhythm Society. Open access under CC BY-NC-ND license.groups 1 and 2 (P ¼ .89); however, there were statistically
signiﬁcant differences between groups 3 and 1 (P o.0001) and
groups 3 and 2 (Po.0001). The patients in group 2 had an AF-free
outcome to equivalent to those who had PV foci in group 1
(P ¼ .83).
CONCLUSION Success rates can be improved for PAF ablation if
non-PV foci are detected and eliminated.
KEYWORDS Catheter ablation; Atrial ﬁbrillation; Pulmonary vein
isolation; Mapping; Nonpulmonary vein foci
ABBREVIATIONS AAD ¼ antiarrhythmic drug; AF ¼ atrial
ﬁbrillation; CA ¼ catheter ablation; CFAE ¼ complex fractionated
atrial electrogram; CT ¼ crista terminalis; LA ¼ left atrium; LAFW
¼ left atrial free wall; LAPW ¼ left atrial posterior wall; PAF ¼
paroxysmal atrial ﬁbrillation; PV¼ pulmonary vein; SVC¼ superior
vena cava
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Most ectopic beats that initiate paroxysmal atrial ﬁbrillation
(PAF) originate from the pulmonary veins (PVs); thus,
pulmonary vein isolation (PVI) has become the established
treatment strategy.1,2 However, the recurrence rate after PVI
for PAF still is 8% to 37%, despite multiple procedures.3–6
Several studies have addressed the importance of non-PV
foci in PAF,3,4,7–9 which tend to be located at sites such as
the superior vena cava (SVC), left atrial free wall (LAFW),
crista terminalis (CT), coronary sinus ostium, ligament of
Marshall, left atrial appendage, and interatrial septum.4,8,10
Non-PV foci are sometimes difﬁcult to identify and elimi-
nate, with several recent studies reporting that atrial ﬁbrilla-
tion (AF) originating from these sources has a worse
outcome than AF from PV sources.3 However, several ofthese reports failed to consider whether the non-PV foci had
been completely eliminated during the procedures. There-
fore, this study aimed to evaluate the impact of catheter
ablation (CA) targeting the elimination of PAF foci, specif-
ically those at non-PV sites.Methods
Study population
In this study, we investigated 304 consecutive patients with
drug-refractory, symptomatic PAF who underwent their ﬁrst
CA procedure between September 2009 and June 2011.
Patients who had previously experienced AF lasting more
than 24 hours or had severe structural abnormalities
(2 patients with severe mitral regurgitation and 1 with a
huge atrial septal defect) were excluded because we aimed to
assess the importance of AF triggers while minimizing the
inﬂuence of the AF substrates. All patients included in the
study were refractory or intolerant to more than 1 antiar-
rhythmic drug (AAD) before the CA procedure. During thehttp://dx.doi.org/10.1016/j.hrthm.2015.05.003
Figure 1 Positions of catheters for induction of nonpulmonary vein foci.
CS ¼ coronary sinus; CT ¼ crista terminalis; LAPW ¼ left atrial posterior
wall; LSPV ¼ left superior pulmonary vein; RSPV ¼ right superior
pulmonary vein; SVC ¼ superior vena cava.
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The patients were divided into 3 groups on a per protocol
basis: group 1 comprised those without any inducible non-
PV triggers in each session, including repeat procedures;
group 2 comprised those with AF originating from non-PV
triggers, with or without PV triggers, and in whom all non-
PV triggers had been successfully ablated not later than the
ﬁnal procedures; and group 3 comprised patients with AF
originating from non-PV triggers, with or without PV
triggers, but in whom it was impossible to identify the
location of AF foci deﬁnitively and to ablate completely
despite repeat procedures. In group 3, we included those
cases in which complete elimination of the non-PV triggers
had not been possible and those in which we could not
identify or ablate the non-PV foci because the AF was only
induced a few times. The study was approved by the ethical
committee of Kokura Memorial Hospital.
Electrophysiologic study and mapping procedure
AADs were discontinued at least 5 half-lives before CA,
except for amiodarone, which was discontinued at least ﬁve
days before ablation. The presence of LA thrombi was
excluded by transesophageal echocardiography. Each patient
provided written informed consent to undergo electrophy-
siologic study in the fasting state under conscious sedation.
The procedure involved inserting a 20-pole catheter
through the right jugular vein. The proximal portion was
positioned along the SVC and CT, and the distal portion was
placed in the coronary sinus. A 10-pole catheter was
positioned at the His-bundle area to record the His-bundle
potential and to pace the right ventricle.
Following the standard Brockenbrough technique, we
introduced two 10-pole circular mapping catheters and an
ablation catheter into the LA. We estimated the location of
the AF initiation foci using the endocardial atrial activation
sequences from the SVC, CT, His bundle, PV, LA posterior
wall (LAPW), and coronary sinus catheters (Figure 1). An
electroanatomic mapping system (CARTO, Biosense Web-
ster, Diamond Bar, CA; or EnSite, NavX, St. Jude Medical,
St. Paul, MN) was typically used to provide additional
guidance and to minimize ﬂuoroscopy time.
Induction of ectopic beats initiating AF
We analyzed the initiating foci using electrode catheters
when spontaneous ectopic beats initiated AF. When no
spontaneous ectopic beats were observed before the PVI
procedure, we intravenously injected adenosine triphosphate
(ATP, 20–40 mg) to induce AF. After PVI, we used a bolus
injection of ATP during continuous infusion of isoproterenol
(ISP, 1–5 μg/kg/min) to search for non-PV foci. If AF was
not initiated by the ATP and ISP infusion, we induced
sustained AF by rapid atrial pacing during ISP infusion,
which was terminated by intracardiac deﬁbrillation. After
restoration of sinus rhythm, we investigated whether there
had been any spontaneous reinitiation of AF. Non-PV foci
were deﬁned as the earliest ectopic sites where the ectopicbeats initiated AF. Any solitary ectopic beat that did not
initiate AF was excluded from the analysis.Catheter ablation
PVI was performed using 2 circular lines encircling the
ipsilateral PVs in all 3 groups. We aimed to ablate non-PV
foci consecutively in groups 2 and 3. Linear ablation or
complex fractionated atrial electrogram (CFAE) ablation was
added, as appropriate. We created LA roof and ﬂoor linear
lesions to prevent roof-dependent atrial tachycardia when 2
PVI circles were too close (within 1 cm). A 3.5-mm or 4-mm
open-irrigated-tip ablation catheter (ThermoCool, Biosense
Webster, Diamond Bar, CA; or Cool Path, St. Jude Medical,
St. Paul, MN) was used. PVI was considered successful in
the acute setting if all ostial PV potentials recorded on the
circular mapping catheter during sinus rhythm or coronary
sinus pacing had been abolished (ie, entrance block). Exit
block was conﬁrmed by pacing from a circular mapping
catheter with antral pacing from the ablation catheter. When
a non-PV focus was identiﬁed, we performed limited area
ablation of the earliest ectopic sites, LAPW and SVC. For
ectopy from the LAPW, we performed a box-shaped linear
ablation around the ectopy by creating roof and ﬂoor lines.
For ectopy from the SVC, we performed SVC isolation from
a site proximal to the SVC ectopic focus. We performed
linear ablation at the cavotricuspid isthmus in patients with
documented or inducible cavotricuspid isthmus–dependent
atrial ﬂutter. The end-point of the linear lesions was complete
bidirectional conduction block, conﬁrmed by pacing from
the appropriate sites.
Power delivery during radiofrequency ablation was
adjusted for the ablation site, and the temperature at
the ablation catheter as well as the impedance drop was
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monitor and titrate the power delivered to the LAPW.
Follow-up of AF recurrence
Patients were observed in the hospital for 3 days after the
procedure before being evaluated in our cardiology clinic at
1 month, 3 months, and every 1 to 3 months after the
procedure. AADs were prescribed for 4 to 12 weeks if early
recurrence of AF occurred. After that, AADs were discon-
tinued if no AF recurrence was observed.
Patients were scheduled to undergo 24-hour Holter
monitoring or 2-week cardiac event recording after the
procedure at appropriate times. When patients experienced
events suggestive of tachycardia, electrocardiography,
24-hour Holter monitoring, or 2-week cardiac event record-
ing was performed to identify the cause of the clinical
symptoms. Any symptomatic or asymptomatic atrial
tachyarrhythmias (including atrial ﬂutter and procedure-
related atrial tachycardia) were treated as recurrences. The
ﬁrst 3 months after the ablation were considered the blanking
period, and the end-point was recurrence of an atrial
arrhythmia (deﬁned as an atrial arrhythmic episode lasting
for41 minute) 3 or more months after the ablation. If more
than 2 recurrence episodes were documented, patients were
encouraged to undergo repeat CA.
Statistical analysis
Results are expressed as mean  SD. The demographic and
clinical characteristics of the 3 groups were compared by
analysis of variance for continuous variables and by either
the χ2 test or the G test for categorical variables. Kaplan–
Meier survival analysis with a log-rank test was used to
assess the recurrence of AF, and logistic regression analysis
was used for multivariate analysis. In all analyses, P o.05
was considered signiﬁcant. Analyses were conducted using
Stat-View 5.0 software (SAS Institute, Cary, NC).Figure 2 Study design and patient ﬂow. CA ¼ catheter ablation;Results
Baseline and electrophysiologic characteristics
The study included 304 patients (age 63.1 10.4 years, 209
males) divided into 3 groups: group 1 (245 patients), group 2
(34 patients), and group 3 (25 patients) according to the
criteria deﬁned in the Methods. The presence of PV foci was
not considered in our deﬁnition of grouping. All patients
underwent CA procedures for drug-refractory symptomatic
AF, with 419 CA procedures performed among them.
A second procedure was necessary in 100 patients (32.9%), a
third procedure in 13 patients (4.3%), and more than 3
procedures in 1 patient (0.3%). Among patients without
non-PV foci at the time of the ﬁrst session, non-PV foci were
newly identiﬁed at the second procedure in 17 patients and at
the third procedure in 3 patients (Figure 2). Baseline and
electrophysiologic characteristics of the 3 groups are listed in
Table 1. There were no signiﬁcant differences in the demo-
graphic or echocardiographic proﬁles.Catheter ablation
Electrical PVI was complete for all patients. If LA–PV
reconnections were present, PVI was accomplished during
repeat procedures. In group 1, an LA roof line was created
after PVI in 28 patients, and an additional LA ﬂoor line was
created in 22 patients to prevent roof-dependent atrial ﬂutter.
In groups 2 and 3, ablation of the non-PV foci was attempted
in addition to PVI for all patients. Ablation of non-PV foci
was primarily by limited focal area ablation, segmental SVC
isolation, LA roof line creation, and additional LA ﬂoor line
creation, as summarized in Table 2. Mitral isthmus lines and
CFAE ablation were rarely performed. In group 2, radio-
frequency pulses were successfully applied to eliminate the
non-PV foci. In group 3, we aggressively searched for non-
PV foci and intensively ablated them. However, it was
difﬁcult to identify the precise foci because of the low
inducibility, or elimination was difﬁcult because of multiplePAF ¼ paroxysmal atrial ﬁbrillation; PV ¼ pulmonary vein.
Table 1 Patient characteristics
Group 1 (N ¼ 245) Group 2 (N ¼ 34) Group 3 (N ¼ 25) P value
General characteristics
Female/male 71/174 11/23 13/12 NS
Age (years) 63.0  10.7 64.8  9.3 61.1  9.6 NS
CHADS2 score 0.9  1.0 1.0  1.2 0.9  1.0 NS
CHA2DS2–VASc score 1.8  1.5 1.9  1.5 2.2  1.6 NS
Hypertension 119 (48.6%) 12 (35.3%) 13 (52%) NS
Diabetes 31 (12.6%) 6 (17.6%) 2 (8%) NS
Stroke/transient ischemic attack 21 (8.6%) 3 (8.8%) 2 (8%) NS
Chronic heart failure 9 (3.7%) 2 (5.9%) 1 (4%) NS
Cardiomyopathy 11 (4.5%) 0 1 (4%) NS
Vascular disease 22 (9.0%) 1 (2.9%) 1 (4%) NS
Coronary artery disease 16 (6.5%) 1 (2.9%) 0 NS
Sick sinus syndrome 32 (13.1%) 5 (14.7%) 3 (12%) NS
Echocardiographic parameters
Left atrial dimension (mm) 38.9  5.4 38.3  5.5 38.5  7.0 NS
Left atrial volume/body mass index 31.6  11.1 30.6  13.3 28.8  7.6 NS
Left ventricular ejection fraction (%) 65.3  7.2 65.5  5.1 64.9  6.7 NS
E/Ea 11.6  4.6 12.6  6.2 12.0  6.8 NS
Follow-up (months) 27.1  11.7 24.2  13.0 28.7  11.7 NS
Ea ¼ early diastolic velocity of the septal mitral annulus.
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ablation procedure, pericardial effusions developed in 2
patients in group 1 and in 1 patient in group 3; they were
resolved by pericardiocentesis. No procedures were aborted.
Recurrence of AF
Mean follow-up after the last procedure was 26.9  11.8
months. During this period, 121 patients (39.8%) had
recurrent AF after a single ablation procedure. Recurrence
rates were 32.7% for group 1, 67.6% for group 2, and 88.0%
for group 3 after a single ablation procedure. In total, 115
repeat ablation procedures were performed in 100 patients
(32.9%), and the overall recurrence rate was 14.5% after
multiple procedures (1.4  0.6 ablation procedures per
patient). No roof-dependent atrial tachycardias occurred
during the follow-up period. Moreover, multivariate analysis
revealed that linear ablation was not an independent pre-
dictor of AF recurrence, with unsuccessful ablation of non-
PV foci being the only independent predictor in that analysis
(Table 3).
Kaplan–Meier survival analysis revealed that the AF
recurrence rate after the last procedure (Figure 3) was
signiﬁcantly higher in group 3 than in groups 1 (68.0% vs
9.8%, P o .0001) and 2 (68.0% vs 8.8%, P o .0001).Table 2 Characteristics of the ablation procedures
Group 1 (N ¼ 245)
Sessions 1.3  0.5
Superior vena cava isolation 6 (2.5%)
Limited area ablation for non-PV foci 0
LA roof line 28 (11.4%)
LA ﬂoor line 22 (9.0%)
Mitral isthmus line 0
CFAE ablation 1 (0.4%)
CTI block line 155 (63.3%)
CFAE ¼ complex fractionated atrial electrogram; CTI ¼ cavotricuspid isthmus;Figure 4 shows the Kaplan–Meier curves for AF recurrence
after the last procedure between the patients in group 2 and
group 1 with PV foci. Of note, no signiﬁcant differences in
AF recurrence were observed between the 2 groups
(P ¼ .89).
Incidence and distribution of PV and non-PV foci
In groups 1, 2, and 3, the PV foci occurred in 42.9% (n ¼
105), 44.1% (n ¼ 15), and 60.0% (n ¼ 15), respectively (not
signiﬁcant). In group 1, 57.1% of patients (n ¼ 140) had no
evidence of foci and successfully underwent PVI. In this
subgroup, the AF recurrence rate was 11.4%, and there were
no signiﬁcant differences compared with that of the patients
with PV foci in group 1. The overall incidence of non-PV
triggers was 19.4% (n ¼ 59). Table 4 summarizes the
distribution AF foci per group. In group 3, they were located
in the LAFW/LA roof (n ¼ 1), SVC (n ¼ 2), and CT/right
atrium (n ¼ 1); however, other non-PV foci remained
indeﬁnitely in all cases.
Regarding the AF originating from different triggers, 8 of
105 patients (7.6%) had recurrence because of PV triggers, 2
of 15 (13.3%) because of SVC triggers, 1 of 6 (16.7%)
because of LAFW triggers, 1 of 7 (14.3%) because of CT
triggers, and 1 of 5 (20%) because of interatrial septumGroup 2 (N ¼ 34) Group 3 (N ¼ 25) P value
1.8  0.7 1.8  0.8 o.0001
16 (47.1%) 4 (16%) o.001
16 (47.1%) 8 (32%) o.001
15 (44.1%) 10 (40%) o.001
14 (41.1%) 8 (32%) o.001
0 1 (4%) NS
1 (2.9%) 1 (4%) NS
27 (79.4%) 15 (60%) NS
LA ¼ left atrium; PV ¼ pulmonary vein.
Table 3 Multivariate predictors of atrial ﬁbrillation recurrence
Variable Hazard ratio (95% conﬁdence) P value
Age 1.00 (0.95–1.04) .72
Sex 0.46 (0.19–1.11) .09
Left atrial volume/body mass index 0.98 (0.95–1.02) .36
Performed linear ablation 1.39 (0.47–4.12) .56
Unsuccessful ablation of nonpulmonary vein foci 25.5 (7.67–84.6) o.0001
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sinus ostium, persistent left SVC, or ligament of Marshall
triggers in group 2.
Discussion
Most PAF ablation procedures are performed anatomically
by isolating all of the PVs at the antrum. However, recurrent
AF occasionally is related to non-PV foci even when all 4
PVs are successfully isolated. This study demonstrated that
application of radiofrequency energy in non-PV areas was an
effective and safe treatment of PAF and emphasized the
importance of detecting and eliminating non-PV foci.
Main ﬁndings
First, we found that the AF recurrence rate was signiﬁcantly
higher in patients with AF originating from non-PV foci and
in those in whom the non-PV triggers were incompletely
eliminated. Second, there was no signiﬁcant difference in AF
recurrence rates between patients in whom only PV foci were
detected and those with non-PV foci that were all success-
fully ablated. Third, each AF recurrence rate among the
various AF foci will be low if we can detect and ablate them.
Incidence and distribution of non-PV foci
In the present study, we only treated AF-initiating ectopic
beats as non-PV foci, even if AF was only induced a few
times during the induction test. Using these criteria, 19.4% of
patients had non-PV foci, with SVC triggers being the most
common (5.6%). Previous reports have either consideredFigure 3 Kaplan–Meier survival curves showing the signiﬁcant differ-
ences in rates of freedom from atrial ﬁbrillation between groups 1 and 3 and
between groups 2 and 3. P¼ .8942 for groups 1 and 2; Po .0001 for group
1 and 3; P o .0001 for groups 2 and 3 (log-rank).non-PV foci to include frequent ectopic beats that did not
induce AF or excluded non-PV foci that could not be
accurately mapped.3,4,9 Clinically, it is not always possible
to identify the non-PV source with our current mapping tools
because sometimes only 1 ectopic beat initiates AF or
because non-PV foci cannot be reproducibly induced, even
with dedicated induction. To our knowledge, this is the ﬁrst
report to include only non-PV foci that induced AF together
with non-PV foci that could not be mapped precisely. We did
this to evaluate the impact of CA that aimed to eliminate
PAF-inducing foci, including the non-PV foci.Patient and electrophysiologic characteristics for AF
from non-PV areas
It is possible that the higher recurrence rate in the patients
from group 3 was observed because of additional remodeling
of the atria compared with patients in groups 1 and 2. In a
previous report, the non-PV foci of the left atria (LA) were
implicated in higher AF recurrence rates because, unlike
right-sided ectopy, left-sided non-PV ectopy is related to
anatomic or electrical remodeling.4 According to other
reports, the presence of non-PV triggers may reﬂect a greater
degree of atrial anatomic remodeling in patients who have an
enlarged left atrial diameter, resulting in poorer out-
comes.3,11 In our cohort, there were no signiﬁcant differ-
ences in with regard to age, LA dimension, LA volume,
ejection fraction, E/Ea, or heart failure morbidity rates
among the 3 groups. Thus, there was no apparent evidence
of anatomic remodeling in patients from group 3 compared
to the other groups in the study. According to a previousFigure 4 Kaplan–Meier survival curves showing no signiﬁcant differ-
ences in rates of freedom from atrial ﬁbrillation between group 2 and patients
with pulmonary vein (PV) foci in group 1. P ¼ .8316 (log-rank).
Table 4 Distribution of the foci of atrial ﬁbrillation
PVs SVC LAPW CT IAS CSO PLSVC LOM
Group 1 (N ¼ 245) 105 - - - - - - -
Group 2 (N ¼ 34) 15 15 6 7 5 3 2 1
Group 3 (N ¼ 25) 15 2 1 1 - - - -
CSO ¼ coronary sinus ostium; CT ¼ crista terminalis; IAS ¼ interatrial septum; LAPW ¼ left atrial posterior wall; LOM ¼ ligament of Marshall;
PLSVC ¼ persistent left superior vena cava; PV ¼ pulmonary vein; SVC ¼ superior vena cava.
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Although there were no signiﬁcant differences among the 3
groups in our cohort, women did tend to have a high
morbidity of non-PV foci (P ¼ .08). This may indicate that
we should take extra care when assessing the presence of
non-PV foci in women during CA.Impact of eliminating non-PV foci in PAF patients
The mid- to long-term freedom from AF recurrence after CA
for PAF is reported to be 63% to 92%.3–6 In this follow-up
cohort, the overall freedom from AF recurrence was 60.2%
after a single procedure, which improved to 85.5% after
multiple procedures. Additionally, several studies indicated
that non-PV sources account for 16% to 28% of PAF,3,4,7–9
whereas the overall incidence of non-PV triggers was 19.4%
in this study. Both of these results were comparable to the
previous reports, indicating that our induction protocols and
ablation procedures were justiﬁed.
According to recent reports of the long-term efﬁcacy of
cryoballoon ablation, the rates of freedom from AF were
65.1% to 76.9% despite repeat procedures.12,13 Compared with
our results, these reports suggest that it is impossible to
eliminate AF in approximately 20% of cases with non-PV foci.
In groups 2 and 3 combined, the AF recurrence rate in
those patients with persistent non-PV foci after the last
procedure was 33.9%, which was similar to that previously
reported (37%).4 However, many previous reports did not
consider whether the non-PV foci had been completely
eliminated during the procedures, which is an important
consideration when evaluating outcomes.
A previous report indicated that the major etiologies for
AF recurrence included reconnections of isolated PVs and
recovery from previously ablated PV triggers.14 However,
we found no signiﬁcant differences among the 3 groups in
the incidences of PV triggers (group 1: 42.9%; group 2:
44.1%; group 3: 60.0%; not signiﬁcant) or LA–PV recon-
nections in second ablations (group 1: 98.6%; group 2: 95%;
group 3: 100%, not signiﬁcant). Thus, the PV triggers did not
inﬂuence the discrepancy in recurrence rates among the 3
groups. In our cohort, the incidence of PV triggers was
relatively low (44.4%) because we only induced AF with
ATP before PVI to proceed with CA for PAF efﬁciently.
In addition, the presence of non-PV foci in our cohort was
associated with a higher AF recurrence rate after the ﬁrst CA
(67.6% for group 2 and 88.0% for group 3). However,
providing the non-PV foci were precisely detected and
eliminated, the presence of non-PV foci was not associated
with recurrence after the last procedure. Moreover, AForiginated from various non-PV foci in group 2, and each
AF recurrence rate for AF originating from these different
foci was low.
Our results indicate 2 important facts. First, it is difﬁcult
to map all non-PV triggers in a single procedure. Second, it is
important to detect and eliminate all AF foci. Furthermore, if
we were able to detect and eliminate non-PV foci, they did
not inﬂuence the AF recurrence rate, and we could expect
improved outcomes.
It remains true that the long-term outcomes after CA in
patients with long-standing persistent AF patients are unsat-
isfactory.15 Therefore, it may be necessary to abolish all non-
PV foci if we are to improve the outcomes of PAF ablation
procedures and prevent the progression of PAF into
persistent AF.Study limitations
This study was performed on a per protocol basis. It is
common for repeated procedures to be performed because of
AF recurrence, and, as indicated in this study, occasionally it
is difﬁcult to ﬁnd all non-PV foci in a single procedure.
Therefore, we analyzed on a per protocol basis instead of an
intention-to-treat basis to evaluate the importance of non-PV foci
ablation. We analyzed our cohort on an intention-to-treat basis as
a sensitivity analysis, and the results are consistent with those
obtained by a per protocol basis approach (data not shown).
The true incidence of AF recurrence in our population was
uncertain because we focused on PAF, and sometimes it was
difﬁcult to detect patients with asymptomatic attacks. However,
we attempted to maximize the detection rate for AF recurrence
by carefully analyzing medical histories and performing
24-hour Holter monitoring or 2-week cardiac event recordings.
CFAE16,17 and LA linear18 ablation are other recognized
treatment approaches for PAF. In previous studies, non-PV
triggers were found to be associated with the presence of
CFAE.19 However, whether these results can be repeated in
other studies is unknown. The effect of LA linear ablation on
PAF also is controversial,18 and the superiority of additional
linear ablation is uncertain. We did not perform aggressive
linear or CFAE ablation because of the possibility of
preventing late occurrences of LA tachycardia. Therefore,
we could not compare the effects between focal ablation and
linear or CFAE ablation for non-PV foci in this study.Conclusion
CA that targets non-PV foci is effective when foci have been
identiﬁed. Therefore, it is important to detect any non-PV
Heart Rhythm, Vol 12, No 9, September 20151924foci and eliminate them during ablation if we are to prevent
avoidable AF recurrence.
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1199–1205.CLINICAL PERSPECTIVES
The recurrence rate of paroxysmal atrial ﬁbrillation (PAF) is 8% to 37% despite repeated pulmonary vein (PV) isolation,
and the catheter ablation (CA) strategy for PAF with non-PV foci is unclear. Clinically, identifying the non-PV source with
available mapping tools may not be possible because occasionally only 1 ectopic beat initiates AF or because non-PV foci
cannot be reproducibly induced, even with dedicated induction. To our knowledge, this is the ﬁrst report to include only
non-PV foci that induced AF with non-PV foci that could not be mapped precisely. Our goal was to evaluate the impact of
CA performed for eliminating PAF-inducing foci, including non-PV foci. We found that the AF recurrence rate was
signiﬁcantly higher in patients with AF originating from non-PV foci and in those in whom the non-PV triggers were
incompletely eliminated. However, no signiﬁcant difference was observed in the AF recurrence rates between patients in
whom only PV foci were detected and those with non-PV foci that were successfully ablated. Moreover, no signiﬁcant
differences were observed in AF recurrence rates among the various AF foci, including non-PV foci. We propose that the
success rates for PAF ablation can be improved if all non-PV foci are detected and eliminated. Our results are clinically
applicable to improve CA outcomes in PAF. We emphasize that there are patients suffering from AF induced by non-PV
foci; therefore, it is important to detect any non-PV foci and eliminate them during ablation to prevent avoidable AF
recurrence.
